Bionow

National Biomanufacturing Centre

The NBC is a government funded initiative, directly developed as part of the Bionow porfolio and currently owned by NWDA. It is one of Europe's leading biopharmaceutical design centres, capable of working with SMEs to develop and manufacture a wide variety of novel biopharmaceutical medicines for early phase clinical trials. The facility can carry out initial manufacture of biopharmaceuticals which can then be used in early stage trials and plugs an essential gap that currently exists to speed up transfer from research to commercial exploitation.

Description

The National Biomanufacturing Centre is a £34 million programme to provide a state of the art biomanufacturing facility, in Speke, Liverpool, which is operated by Eden Biodesign, now part of Watson Pharmaceuticals. The 4100 m2 facility can provide the full range of services necessary to take a novel biopharmaceutical from proof of concept through to cGMP manufacture for clinical trials. 

Benefits

The National Biomanufacturing Centre is an innovative vehicle for the delivery of much needed expertise and manufacturing capability to early stage biotechnology companies and product development programmes. Other outputs include a graduate training programme. The resulting impact will not only ensure medical evaluation of innovative products that might not otherwise be developed but will also encourage the growth of the UK biomanufacturing industry, supporting pipeline development for SMEs, contract manufactures and large sponsor companies, thereby ensuring that we play a leading role in this growth market.

For more details visit the Eden Biodesign website.